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Coronary heart disease (CHD) is the single leading cause ofdeath and a significant cause of morbidity among American
women (1). Risk factors for CHD in women are well documented
(2). Compelling data from epidemiological studies and randomized
clinical trials show that CHD is largely preventable. Assessment and
management of several risk factors for CHD are cost-effective (3).
Despite these facts, there are alarming trends in the prevalence and
management of risk factors in women (2). Smoking rates are
declining less for women than for men. The prevalence of obesity is
increasing, and '25% of women report no regular sustained
physical activity (4). Approximately 52% of women .45 years old
have elevated blood pressure, and '40% of women .55 years old
have elevated serum cholesterol (5). The purpose of this statement
is to highlight risk factor management strategies that are appropriate
for women with a broad range of CHD risk. A more detailed
description, including the scientific basis for these recommenda-
tions, is available in the 1997 American Heart Association scientific
statement “Cardiovascular Disease in Women” (2).
Recently, the Centers for Disease Control and Prevention Na-
tional Ambulatory Medical Care Survey (6) showed clinicians are
missing opportunities to prevent CHD. In this study of 29 273
routine office visits, women were counseled less often than men
about exercise, nutrition, and weight reduction. In the multicenter
Heart and Estrogen/progestin Replacement Study (HERS) (7), only
10% of women enrolled with documented CHD had baseline
LDL-cholesterol levels below a National Cholesterol Education
Program (NCEP) target of 100 mg/dL. A recent national survey
showed that women were significantly less likely than men to enroll
in cardiac rehabilitation after an acute myocardial infarction (MI) or
bypass surgery (8). This finding is especially important because
post-MI patients not enrolled in cardiac rehabilitation are less likely
to receive aggressive risk factor management.
Recommendations for the primary and secondary prevention of
CHD have been published (9,10). Although those recommenda-
tions apply to women, there are aspects of risk factor management
that are unique to women. Pregnancy and the preconception period
are optimal times to review a woman’s risk factor status and health
behaviors to reduce future cardiovascular disease. Pregnant women
should be strongly encouraged to discontinue smoking and not to
relapse in the postpartum period. Avoidance of excess weight gain
during pregnancy may reduce the risk of developing CHD in the
future. An emphasis on prevention of CHD in postmenopausal
women is particularly important because the incidence of CHD rises
with age. The use of estrogen replacement therapy (ERT) to prevent
CHD, osteoporosis, and possibly dementia is a difficult health
decision for postmenopausal women. The potential benefits of
therapy must be weighed against the possible risks, including breast
cancer, gallbladder disease, thromboembolic disease, and endome-
trial cancer, although the last is reduced by concomitant use of a
progestin.
The recent findings from HERS (11) have challenged previ-
ous observational data regarding the role of hormones in
preventing subsequent cardiovascular events. HERS was the
first large-scale, randomized, clinical trial in older postmeno-
pausal women with confirmed coronary disease to test the
efficacy and safety of hormone replacement therapy on clinical
cardiovascular outcome in postmenopausal women. The study
population included 2763 women (mean age 66.7 years) with
established CHD randomly assigned to 0.625 mg conjugated
equine estrogens (CEE) plus 2.5 mg of medroxyprogesterone
acetate (MPA) per day or placebo. Participants were monitored
for an average of 4.1 years for the main end point of nonfatal MI
or CHD death. At study completion, no significant differences
existed between groups for any cardiovascular end points.
Surprisingly, after 1 year, HERS showed an increase in cardio-
vascular events in the treatment arm, but in years 4 and 5, fewer
events occurred than in the placebo arm. It has been hypothesized
that possible early adverse effects of estrogen in women with CHD
may be due to a procoagulant effect that may later be offset by an
antiatherogenic benefit. MPA may also have adverse cardiovascular
effects and may mitigate some of the beneficial effects of estrogen
(2). Although these hypotheses deserve further investigation, the
overall null result from HERS does not support initiation of CEE
combined with MPA in older postmenopausal women with con-
firmed coronary disease. For women with CHD already on ERT for
$1 year, it may be reasonable to continue therapy while awaiting
the results of a HERS follow-up study and other ongoing trials of
ERT with clinical end points. The results of the HERS trial apply to
women with preexisting CHD and may not apply to women free of
vascular disease. Furthermore, this study does not take into consid-
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eration the other potential benefits of this therapeutic protocol,
which are beyond the scope of this statement.
Data are lacking for determining the long-term cardiovascular
effects of testosterone administered with ERT. Alternatives to
traditional hormone replacement therapy are available, including
soy phytoestrogens and selective estrogen receptor modulators
(SERMs); however, a recommendation regarding their use for
prevention of CHD has not been made at this time because of a
lack of sufficient data.
Several other aspects of risk factor management are of
heightened importance for women. Diabetes is a powerful
risk factor in women, increasing CHD risk 3-fold to 7-fold
compared with a 2-fold to 3-fold increase in risk in men (12).
This difference may be due to a particularly deleterious effect
of diabetes on lipids and blood pressure in women (2,12).
Therefore, recommendations are provided for management of
diabetes with an emphasis on controlling concomitant risk
factors (13). Low levels of HDL cholesterol are predictive of
CHD in women and appear to be a stronger risk factor for
women .65 years old than for men .65 (14). Women tend
to have higher HDL-cholesterol levels than men, and triglyc-
eride levels may be a significant risk factor in women,
especially older women. The current NCEP guidelines are
outlined in the Table with a notation to consider more
aggressive targets for HDL cholesterol and triglycerides in
women (15). The NCEP also recommends the use of ERT
before cholesterol-lowering drugs to reduce LDL cholesterol
in postmenopausal women. In this statement, the recommen-
dation has been modified to consider statins a first-line
therapy in postmenopausal women on the basis of recent data
that suggest women may have at least as much benefit from
LDL-cholesterol reduction with statins as men (16).
Recommendations for aggressive risk factor management
are based on the future probability of a cardiovascular event.
This strategy allows high-risk patients who have not yet had
an event to be considered for more intensive treatment (17).
It also recognizes that CHD is not a categorical event but
rather a continuum of a progressive disease process. As the
availability and use of noninvasive tools to detect asymptom-
atic CHD increase, the line between primary and secondary
prevention may become less distinct. Substantial data support
aggressive risk factor management in the setting of secondary
prevention. However, because first cardiovascular events are
often fatal in women, careful consideration should be given to
individual risk factor management before onset of clinical
CHD in women. The current recommendations are developed
from previous guidelines and consensus panel statements
along with newer gender-specific data when available
(2,9,10,13,15,18–23). The recommendations can serve as a
guide to risk factor management but cannot replace clinical
judgment. As new knowledge is acquired, revised strategies
for the prevention of CHD in women should reflect new
science.
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Guide to Risk Reduction for Women
Lifestyle Factors Goal(s) Screening Recommendations
Cigarette smoking 1. Complete cessation.
2. Avoid passive cigarette smoke.
1. Ask about current smoking status
and exposure to others’ cigarette
smoke as part of routine evaluation.
2. Assess total exposure to cigarette
smoke (pack-years) and prior
attempts at quitting.
3. Evaluate readiness to stop
smoking.
1. At each visit, strongly encourage patient and
family to stop smoking. If complete cessation is
not achievable, a reduction in intake is beneficial
as a step toward cessation.
2. Reinforce nonsmoking status.
3. Provide counseling, nicotine replacement, and
other pharmacotherapy as indicated in
conjunction with behavioral therapy or a formal
cessation program.
Physical activity 1. Accumulate $30 min of
moderate-intensity physical activity
on most, or preferably all, days of
the week.
2. Women who have had recent
cardiovascular events or procedures
should participate in cardiac
rehabilitation, a physician-guided
home exercise program, or a
comprehensive secondary prevention
program.
1. Ask about physical activity
(household work as well as
occupational and leisure-time physical
activity) as part of routine evaluation.
2. In women with symptoms that
suggest CVD or in previously
sedentary women .50 y old with $2
risk factors for CVD, consider a stress
test* to establish safety of exercise
and to guide the exercise prescription.
1. Encourage a minimum of 30 min of
moderate-intensity dynamic exercise (eg, brisk
walking) daily. This may be performed in
intermittent or shorter bouts ($10 min) of
activity throughout the day.
2. Women who already meet minimum standards
may be encouraged to become more physically
active or to include more vigorous activities.
3. Incorporate physical activity in daily activities
(eg, using stairs).
4. Muscle strengthening and stretching exercises
should be recommended as part of an overall
activity program.
5. Recommend medically supervised programs
for women who have had a recent MI or
revascularization procedure.
Nutrition 1. AHA Step I Diet in healthy women
(#30% fat, 8–10% saturated fat,
and ,300 mg/d cholesterol).
2. AHA Step II Diet in women with
CVD or if a further reduction in
cholesterol is needed (#30% fat,
,7% saturated fat, and ,200 mg/d
cholesterol).
3. Limit sodium chloride (salt) intake
to 6 g/d. Women with high blood
pressure may require further
restriction.
4. Total dietary fiber intake of
25–30 g/d from foods.
5. Consume $5 servings of fruits
and vegetables per day.
1. Assess nutritional habits as part of
a routine evaluation in all women.
2. Consider formal dietary assessment
in women with hyperlipidemia,
diabetes, obesity, and hypertension.
1. Encourage a well-balanced and diversified diet
that is low in saturated fat and high in fiber.
2. Use skim milk instead of milk with a higher
fat content.
3. Diets rich in antioxidant nutrients (eg, vitamin
C, E, and beta-carotene) and folate are preferred
over nutritional supplements. Note: Daily
supplements of 0.4 mg of folic acid are
recommended for women of child-bearing age to
help prevent neural tube defects.
4. Limit alcohol intake to #1 glass of alcohol per
day. (1 glass54 oz wine, 12 oz beer, or 11⁄2 oz
80-proof spirits.) Pregnant women should abstain
from drinking alcohol.
Weight management 1. Achieve and maintain desirable
weight.
2. Target BMI (weight in kilograms
divided by height in meters squared)
between 18.5 and 24.9 kg/m2 (BMI
of 25 kg/m25110% of desirable
body weight).
3. Desirable waist circumference
,88 cm (,35 inches) in women
with a BMI of 25–34.9 kg/m2.
Measure patient’s weight and height,
calculate BMI, and measure waist
circumference as part of a periodic
evaluation.
Note: BMI and waist circumference
are used for diagnosis, and
measurement of height and weight
are used for follow-up.
1. Encourage gradual and sustained weight loss
in persons whose weight exceeds the ideal
weight for their height.
2. Formal nutritional counseling is encouraged for
women with hypertension, hyperlipidemia, or
elevated glucose levels associated with overweight.
3. The recommended weight gain during pregnancy
is 25–35 lb if the patient’s prepregnancy weight is
normal. Adjust for multiple gestation and
prepregnancy weight (eg, overweight women should
gain 15–25 lb, obese women, ,15 lb).
Mosca et al May 1999 1753
Continued
Lifestyle Factors (continued) Goal(s) Screening Recommendations
Psychosocial factors 1. Positive adaptation to stressful
situations.
2. Improved quality of life.
3. Maintain or establish social
connections.
1. Assess presence of stressful
situations and response to stress as
part of a routine evaluation.
2. Evaluate for depression, especially
in women with recent cardiovascular
events.
3. Assess social support system and
evaluate for social isolation.
1. Encourage positive coping mechanisms for stress
(eg, substitute physical activity for overeating or
excessive smoking in response to stress).
2. Encourage adequate rest and relief for women who
are caretakers of others.
3. Consider treatment of depression and anxiety when
appropriate.
4. Encourage participation in social activities or
volunteer work for socially isolated women.
Risk Factors Goals Screening Recommendations
Blood pressure 1. Achieve and maintain blood
pressure ,140/90 mm Hg and lower
if tolerated (optimal ,120/80).
2. In pregnant women with
hypertension, the goal of treatment is
to minimize short-term risk of
elevated blood pressure in the
mother while avoiding therapy that
may compromise the well-being of
the fetus.
1. Measure blood pressure as part of
a routine evaluation.
2. Follow-up is based on initial
measurement as follows:
SBP, DBP,
mm Hg mm Hg Follow-up
,130 ,85 Recheck in 2 y
130–139 85–89 Recheck in 1 y
140–159 90–99 Confirm in 2 mo
160–179 100–109 Evaluate in 1 mo
$180 $110 Evaluate in 1 wk
(Follow-up screening may be modified
on the basis of prior history,
symptoms, presence of other risk
factors, and end organ damage.)
3. In pregnant women with
hypertension, evaluate for
preeclampsia.
1. Promote the lifestyle behaviors described above
(weight control, physical activity, moderation in
alcohol intake) and moderate sodium restriction.
2. If blood pressure remains $140/90 mm Hg after
3 months of lifestyle modification or if initial level
is .160 mm Hg systolic or 100 mm Hg diastolic,
then initiate and individualize pharmacotherapy
based on the patient’s characteristics.
3. In pregnant women with hypertension, reduction
of diastolic blood pressure to 90–100 mm Hg is
recommended.
Lipids, lipoproteins Primary goal:
Women without CVD
Lower risk (,2 risk factors)
LDL goal ,160 mg/dL (optimal
,130 mg/dL)
Higher risk ($2 risk factors)
LDL goal ,130 mg/dL
Women with CVD
LDL #100 mg/dL
Secondary goals:
HDL .35 mg/dL
Triglycerides ,200 mg/dL
Note: In women, the optimal level of
triglycerides may be lower (#150
mg/dL) and the HDL higher ($45
mg/dL).
Women without CVD†
Measure nonfasting total and HDL
cholesterol and assess nonlipid risk
factors. Follow-up is based on the
following initial measurements:
TC ,200, HDL $45, follow-up in 5
years; TC ,200, HDL ,45, follow-up
with fasting lipoprotein analysis. TC
200–239, HDL $45, and ,2 risk
factors, follow-up in 1–2 years. TC
200–239, HDL ,45 or $2 risk
factors, follow-up with fasting
lipoprotein analysis. TC $240,
follow-up with fasting lipoprotein
analysis. (All cholesterol values in
mg/dL.)
Women with CVD
Fasting lipoprotein analysis (may take
4–6 wk to stabilize after
cardiovascular event or bypass
surgery).
1. Promote lifestyle approach in all women (diet,
weight management, smoking avoidance, and
exercise as described above). Rule out other
secondary causes of dyslipidemia.
2. Suggested drug therapy for high LDL levels
(defined as [a] $220 mg/dL in low-risk,
premenopausal women, [b] $190 mg/dL in
postmenopausal women with ,2 risk factors, and
[c] $160 mg/dL with $2 risk factors) is based on
triglyceride level as follows:
TG ,200 mg/dL
Statin, Resin, Niacin
Note: ERT is an option for postmenopausal women,
but treatment should be individualized and
considered with other health risks.
TG 200–400 mg/dL
Statin, Niacin
TG .400 mg/dL
Consider monotherapy with statin, niacin, fibrate,
or a combination of the above.
Diabetes For patients with diabetes:
1. Maintain blood glucose:
preprandial580–120 mg/dL
bedtime5100–140 mg/dL.
2. Maintain Hb A1c ,7%.
3. LDL ,130 mg/dL (,100 mg/dL if
established CVD). Note: Many
authorities believe that LDL should be
,100 mg/dL in all patients with
diabetes.
4. Triglycerides ,150 mg/dL.
5. Control blood pressure.
1. Monitor glucose and hemoglobin
A1c as part of a routine periodic
evaluation in women with diabetes.
2. Screen for diabetes (fasting glucose
.125 mg/dL or .200 mg/dL 2 h
after 75 g glucose) as part of a
periodic examination in women with
risk factors for diabetes, such as
obesity.
1. Encourage adoption of American Diabetes
Association Diet (,30% fat, ,10% saturated fat,
6–8% polyunsatured fat, cholesterol ,300 mg/d).
2. A low-calorie diet may be recommended for
weight loss.
3. Encourage regular physical activity.
4. Pharmacotherapy with oral agents or insulin
should be used when indicated.
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Pharmacological
Interventions Goal(s) Screening Recommendations
Hormone replacement
therapy
1. Initiation or continuation of therapy
in women for whom the potential
benefits may exceed the potential
risks of therapy. (Short-term therapy
is indicated for treatment of
menopausal symptoms.)
1. Review menstrual status of women
.40 y old.
2. If menopausal status is unclear,
measure FSH level.
1. Counsel all women about the potential
benefits and risks of HRT, beginning at age 40 or
as requested.
2. Individualize decision based on prior history and
risk factors for CVD as well as risks of
thromboembolic disease, gallbladder disease,
osteoporosis, breast cancer, and other health risks.
2. Minimize risk of adverse side
effects through careful patient
selection and appropriate choice of
therapy.
3. Combination therapy with a progestin is
usually indicated to prevent endometrial
hyperplasia in a woman with an intact uterus
and prescribed estrogen. The choice of agent
should be made on an individual basis.
Oral contraceptives 1. Minimize risk of adverse
cardiovascular effects while
preventing pregnancy.
2. Use the lowest effective dose of
estrogen/progestin.
Determine contraindications and
cardiovascular risk factor status of
women who are considering using
oral contraceptives.
1. Use of oral contraceptives is relatively
contraindicated in women $35 y old who
smoke.
2. Women with a family history of premature
heart disease should have lipid analysis before
taking oral contraceptives.
3. Women with significant risk factors for
diabetes should have glucose testing before
taking oral contraceptives.
4. If a woman develops hypertension while using
oral contraceptives, she should be advised to
stop taking them.
Antiplatelet
agents/anticoagulants
Prevention of clinical thrombotic and
embolic events in women with
established CVD.
1. Determine if contraindications to
therapy exist at the time of the initial
cardiovascular event.
2. Evaluate ongoing compliance, risk,
and side effects as part of a routine
follow-up evaluation.
1. If no contraindications, women with
atherosclerotic CVD should use aspirin
80–325 mg/d.
2. Other antiplatelet agents, such as newer
thiopyridine derivatives, may be used to prevent
vascular events in women who cannot take
aspirin.
b-blockers To reduce the reinfarction rate,
incidence of sudden death, and
overall mortality in women after MI.
1. Determine if contraindications to
therapy exist at the time of the initial
cardiovascular event.
2. Evaluate ongoing compliance, risk,
and side effects as part of a routine
follow-up evaluation.
Start within hours of hospitalization in women
with an evolving MI without contraindications. If
not started acutely, treatment should begin
within a few days of the event and continue
indefinitely.
ACE inhibitors To reduce morbidity and mortality
among MI survivors and patients
with LV dysfunction.
1. Determine if contraindications to
therapy exist at the time of the initial
cardiovascular event.
2. Evaluate ongoing compliance, risk,
and side effects as part of a routine
follow-up evaluation.
1. Start early during hospitalization for MI unless
hypotension or other contraindications exist.
Continue indefinitely for all with LV dysfunction
(ejection fraction #40%) or symptoms of
congestive heart failure; otherwise, ACE inhibitors
may be stopped at 6 wk.
2. Discontinue ACE inhibitors if a woman
becomes pregnant.
CVD indicates cardiovascular disease; BMI, body mass index; SBP, systolic blood prssure; DBP, diastolic blood pressure; TC, total cholesterol; TG, triglycerides;
HRT, hormone replacement therapy; and FSH, follicle-stimulating hormone.
*The choice of test modality should be based on the resting ECG, physical ability to exercise, and local expertise and technologies.
†The ACC and the AHA recommend cholesterol screening guidelines as outlined by the National Cholesterol Education Panel (measure total and HDL cholesterol
at least once every 5 years in all adults $20 y old. The consensus panel recognizes that some organizations use other guidelines, such as the US Preventive Services
Task Force, which recommends that cholesterol screening in women without risk factors begin at age 45 y.
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